CMD patients face a 2x higher risk of dementia and MCI, but healthier lifestyles can counter air pollution's impact and ...

Study highlights a fourfold increase in ME/CFS risk among COVID-19 patients, with 89% of post-COVID ME/CFS cases overlapping ...

A tentative ceasefire has been announced in the ongoing conflict between Israel and Hamas, marking a significant development ...

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

Acceptance of the Biologics License Application for subcutaneous Leqembi is based on results from the Clarity AD open-label ...

Japanese drugmaker Eisai and US partner Biogen announced today that the US Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (US brand name ...

A Potential Game-Changer for Mental Health TreatmentsSetting New Benchmarks: 65% Response Rate Shown in Completed Depression ...

and several other markets for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. Lecanemab's approvals in these countries, as well as the CHMP's ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...

This is the 29 th published study on the use of BrainHQ in patients with MCI or other forms of pre-dementia. Prior studies ...

While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...